Keyhole-limpet haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma.
The antigenicity of transitional cell carcinoma of the bladder has stimulated the search for effective immunotherapeutic agents in the treatment of this disease. Non-specific immunotherapy with local (intravesical/intralesional) and systemic Keyhole Limpet Haemocyanin (KLH) in a FANFT induced murine bladder tumor model was studied. Results showed no difference between control or treated groups in either tumor growth or animal survival.
D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D005200:FANFT; D005260:Female; D006433:Hemocyanins; D007279:Injections, Subcutaneous; D051379:Mice; D008809:Mice, Inbred C3H; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*
D000941:Antigens; D005200:FANFT; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin